Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MDRT with or without 6 months of ADT for oligometastatic recurrent prostate cancer
NL-OMON58617Phase 3Active, not recruiting
- Sponsor
- University Medical Center Groningen
- Start
- Jul 2024
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of leuprolide in prostate cancer (PCa) and recurrent prostate cancer (RPC) (2 arms), sponsored by University Medical Center Groningen. Primary endpoint: 2-year metastases progression-free survival. Started Jul 2024; status: active, not recruiting.
02
Drugs
leuprolide
03
Conditions
prostate cancer (PCa)recurrent prostate cancer (RPC)
Beyond the preview
Go deeper on NL-OMON58617.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58617.